Cargando…
Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-small Cell Lung Cancer Cell Lines
Background: Gefitinib is a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) used to treat EGFR mutation-positive patients with non-small cell lung cancer (NSCLC). However, the efficacy of gefitinib is limited by the development of acquired resistance. Studies have shown tha...
Autores principales: | Wen, Chunjie, Xu, Ge, He, Shuai, Huang, Yutang, Shi, Jingjing, Wu, Lanxiang, Zhou, Honghao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171488/ https://www.ncbi.nlm.nih.gov/pubmed/32328186 http://dx.doi.org/10.7150/jca.39783 |
Ejemplares similares
-
circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway
por: Huang, Yutang, et al.
Publicado: (2020) -
ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018) -
Circular RNAs Are Promising Biomarkers in Liquid Biopsy for the Diagnosis of Non-small Cell Lung Cancer
por: Huang, Lanxiang, et al.
Publicado: (2021) -
miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
por: Ge, Peng, et al.
Publicado: (2019) -
Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)